Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea
- Author:
Hee Yeon LEE
1
;
Ji Hyung HONG
;
Jae Ho BYUN
;
Hee-Jun KIM
;
Sun Kyung BAEK
;
Jin Young KIM
;
Ki Hyang KIM
;
Jina YUN
;
Jung A KIM
;
Kwonoh PARK
;
Hyo Jin LEE
;
Jung Lim LEE
;
Young-Woong WON
;
Il Hwan KIM
;
Woo Kyun BAE
;
Kyong Hwa PARK
;
Der-Sheng SUN
;
Suee LEE
;
Min-Young LEE
;
Guk Jin LEE
;
Sook Hee HONG
;
Yun Hwa JUNG
;
Ho Jung AN
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2020;52(1):277-283
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in earlystage.
Materials and Methods:Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results:Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion:Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.
